Tekla Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Tekla Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.65M	Hold	105,073	–	–	0.06%	117
2023 Q1	$1.73M	Hold	105,073	–	–	0.07%	126
2022 Q4	$1.64M	Hold	105,073	–	–	0.06%	121
2022 Q3	$1.36M	Hold	105,073	–	–	0.06%	123
2022 Q2	$1.48M	Sell	105,073 -105,073	-50%	-$1.5M	0.06%	123
2022 Q1	$3.01M	Hold	210,146	–	–	0.11%	108
2021 Q4	$2.86M	Hold	210,146	–	–	0.09%	118
2021 Q3	$3.44M	Hold	210,146	–	–	0.11%	123
2021 Q2	$3.54M	Hold	210,146	–	–	0.11%	134
2021 Q1	$3.84M	Hold	210,146	–	–	0.13%	134
2020 Q4	$3.83M	Hold	210,146	–	–	0.13%	132
2020 Q3	$3.75M	Hold	210,146	–	–	0.14%	117
2020 Q2	$3.77M	Hold	210,146	–	–	0.14%	120
2020 Q1	$3.19M	Hold	210,146	–	–	0.14%	112
2019 Q4	$4.15M	Hold	210,146	–	–	0.16%	123
2019 Q3	$3.62M	Buy	210,146 +32,018	+18%	+$554K	0.16%	104
2019 Q2	$3.15M	Hold	178,128	–	–	0.13%	117
2019 Q1	$3.63M	Buy	+178,128	New	+$3.58M	0.15%	111

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tekla Capital Management's TAK Position: Q2 2023 in Review

Tekla Capital Management held its Takeda Pharmaceutical (TAK) position steady in Q2 2023 at 105,073 shares worth $1.65M. The position accounts for 0.06% of the portfolio, ranked #117.

Tekla Capital Management first reported a position in TAK in Q1 2019 and has held it in 18 quarters since. The position peaked at $4.15M in Q4 2019. 311 funds tracked by Wall St. Rank hold TAK as of Q2 2023.

Tekla Capital Management held 105,073 shares of Takeda Pharmaceutical worth $1.65M as of Q2 2023.
Tekla Capital Management left its Takeda Pharmaceutical share count unchanged in Q2 2023.
Takeda Pharmaceutical made up 0.06% of Tekla Capital Management's portfolio in Q2 2023, its #117 holding.
Tekla Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 18 quarters since.
Tekla Capital Management's Takeda Pharmaceutical position peaked at $4.15M in Q4 2019.
311 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.